leadf
logo-loader
viewOrthocell Ltd
(
ASX:OCC
)

Orthocell secures new patents for CelGro® suture-less repair of soft tissue

The company’s pre-clinical studies have shown at a microscopic level that CelGro® produces superior nerve repair and return of muscle function in severed peripheral nerves when compared to the traditional (direct suture) repair method.

Orthocell Ltd - Orthocell secures new patents for CelGro® suture-less repair of soft tissue

Orthocell Ltd (ASX:OCC), a regenerative medicine company, has been granted new patents in Canada and Hong Kong for its novel CelGro® collagen medical device platform for soft tissue regeneration applications.

The patents titled ‘Suture-less repair of soft tissue’ have now been granted in Australia, New Zealand, China, Japan, Hong Kong and Canada, with further applications progressing in the US and EU.

Promisingly, the patents cover the method of using CelGro® to repair a defect in soft tissue, such as tendons, ligaments and nerves, avoiding the use of damaging sutures.

“Patents an important addition”

Orthocell managing director Paul Anderson said: “These patents are an important addition to our global intellectual property portfolio, further strengthening our position in regenerative medicine product development and novel surgical techniques for soft tissue repair.

“Suture-less or tensionless repair is of particular importance in the optimal repair of damaged nerves and is a key part of the repair process undertaken in the CelGro® nerve regeneration clinical study.

“This comes at a perfect time for the company as we move our exciting pipeline products in nerve, tendon and ligament repair through the registration process in the US, EU and AUS.”

Superior nerve repair

Suture-less repair of soft tissue refers to the method of repairing damaged soft tissue without the use of damaging sutures/stitches.

This method has the potential to greatly improve the efficiency and efficacy of surgical procedures by simplifying techniques, reducing surgery time and reducing the risk of additional trauma to soft tissue caused by the use of stitches.

Orthocell’s pre-clinical studies have shown at a microscopic level that CelGro® produces superior nerve repair and return of muscle function in severed peripheral nerves when compared to the traditional (direct suture) repair method.

Promisingly, CelGro® has also facilitated a 30% greater transmission of electrical impulses and corresponding muscle function.

Human nerve regeneration study

Orthocell has now completed patient treatments in its CelGro® nerve regeneration clinical study involving 19 patients and 33 nerve repairs.

Positive clinical data shows nerve repair with CelGro® following injury to the spinal cord, brachial plexus and other peripheral arm/hand nerves consistently restore arm and hand function.

Forward plan

Orthocell has now engaged Experien Group as its US regulatory advisory team to evaluate opportunities for expedited approval of CelGro® for nerve regeneration.

The evaluation has been completed and Experien is now developing the US FDA submission to confirm the most appropriate US regulatory pathway, which includes potential for inclusion in expedited programs and clarity regarding the reimbursement value of the product.

Quick facts: Orthocell Ltd

Follow
ASX:OCC

Price: 0.51 AUD

Market Cap: $97.68 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Orthocell looks ahead to results from OrthoATI shoulder tendon study in Q4

Orthocell Ltd (ASX:OCC)'s Paul Anderson tells Proactive they've has passed a key milestone by completing the 12-month follow-up of the last patient treated in the Autologous Tenocyte Injection (OrthoATI®) rotator cuff tendon study. The RC study was designed to assess the effectiveness of...

3 weeks, 3 days ago

3 min read